Global In-Vitro ADME Testing Services Market, 2018-2019 & 2030 - The Likely Evolution of the Market in the Short to Mid-Term and Long Term

News provided by

Mar 25, 2019, 05:00 ET

DUBLIN, March 25, 2019 /PRNewswire/ -- The "In Vitro ADME Testing Services Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The early stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the overall success of a drug candidate in both preclinical and clinical studies. It is also important to note that the process of drug discovery is extremely demanding, both in terms of capital and time.

In fact, the overall amount spent in R&D initiatives in the pharmaceutical/biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early-stage therapeutic candidates are able to make it past preclinical evaluation.

According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity. As a result, the industry is currently under tremendous pressure to not only meet the expectations of a growing patient population but to also identify ways to mitigate the risks associated with discovery programs of novel drug/therapy molecules.

Specifically, ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical/biopharmaceutical market. Moreover, advances in combinatorial chemistry and high throughput screening in the last decade have made it possible to carry out early-stage ADME screening for a large number of compounds in a more cost and time efficient manner.

In less than a decade, the ADME services industry has witnessed noteworthy consolidation, with many of the smaller players being acquired by more established firms in efforts to augment services portfolios and widen geographical reach. Further, given the growing demand for high-quality pharmacological interventions, and the cost and time-related benefits of outsourcing in vitro ADME research, the demand for CROs is projected to grow significantly in the foreseen future.

One of the key objectives of the report is to evaluate the current opportunity and the future potential of the in vitro ADME testing services market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. The Drug Discovery and Development Process
3.3. Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing
3.4. Importance of ADME Studies in Early Stage Research
3.5. Types of ADME Studies in Discovery and Preclinical Development
3.6. Types of Assays Used in ADME Testing
3.7. Types of ADME Testing Studies
3.7.1. In Vitro ADME Testing Studies
3.7.2. In Silico ADME Testing Studies
3.7.3. In Vivo ADME Testing Studies
3.8. Key Drivers for ADME Testing Studies
3.9. Concluding Remarks

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing ADME Testing Services
4.3. Guiding Models for Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance-based Outsourcing Model
4.3.3. Outcomes-based Outsourcing Model
4.3.4. Phase-dependent Outsourcing Model
4.4. Selecting a Contract Research Organization (CRO) Partner
4.4.1. Key Considerations
4.5. Role of CROs in Drug Development
4.5.1. Discovery and Preclinical Research
4.5.2. Early Clinical Research
4.5.3. Late Stage Clinical Research
4.6. Benefits of Outsourcing ADME Testing Services
4.7. Risks and Challenges Associated with Outsourcing ADME Testing Services
4.8. Concluding Remarks

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. In Vitro ADME Testing Services: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Service Offering
5.2.5. Analysis by Type of In Vitro ADME Assays
5.2.6. Analysis by Type of Molecule
5.2.7. Analysis by Type of Clientele
5.2.8. Logo Landscape: Distribution by Company Size and Location of Headquarters
5.3 In Silico ADME Testing Services: List of Industry Players

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Albany Molecular Research (AMRI)
6.2.1.1. Company Snapshot
6.2.1.2. Financial Information
6.2.1.3. ADME Testing Specific Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Charles River Laboratories
6.2.3. Pharmaceutical Product Development (PPD)
6.2.4. RTI International
6.3. Key Players based in Europe
6.3.1. Eurofins Scientific
6.3.1.1. Company Snapshot
6.3.1.2. Financial Information
6.3.1.3. ADME Testing Specific Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Evotec
6.3.3. Galapagos
6.3.4. Tecan Group
6.4. Key Players based in Asia-Pacific
6.4.1. GVK Biosciences
6.4.1.1. Company Snapshot
6.4.1.2. ADME Testing Specific Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Pharmaron
6.4.3. Sai Life Sciences
6.4.4. Shanghai Medicilon
6.4.5. Syngene International
6.4.6. WuXi AppTec

7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.4. Concluding Remarks

8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. In Vitro ADME Testing Services: Mergers and Acquisitions
8.2.1. Cumulative Year-wise Trend
8.2.2. Geographical Activity
8.2.3. Ownership Change Matrix
8.2.4. Most Active Players: Analysis by Number of Acquisitions
8.2.5. Key Value Drivers
8.2.6. Key Acquisitions: Deal Multiples

9. REGULATORY RECOMMENDATIONS AND GUIDELINES
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Regulatory Agencies
9.2.1. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
9.2.2. World Health Organization (WHO)
9.2.3. Organisation for Economic Co-operation and Development (OECD)
9.3. Regulatory Guidelines Issued by Regional Regulatory Agencies
9.3.1. United States Food and Drug Administration (USFDA), US
9.3.2. European Medicine Agency (EMA), Europe
9.3.3. Ministry of Health, Labour and Welfare (MHLW), Japan
9.4. In Vitro ADME Testing Service Providers: Information on Regulatory Approval

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall In Vitro ADME Testing Services Market, 2019-2030
10.4. In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030
10.5. In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030
10.6. In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030
10.7. In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030
10.8. In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030
10.9. In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030

11. CONCLUSION
11.1. In Vitro ADME Studies Conducted During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Success in Clinical Trials
11.2. Several CROs Offer Services for In Vitro ADME Testing; Most such Companies are based in North America and Europe
11.3. The Market is Dominated by Players having Vast In Vitro ADME Testing Portfolios; Drug Metabolism-related Assays Represent a Major Fraction of Services
11.4. Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in Number of Acquisitions Reported over the Past Decade
11.5. Owing to the Benefits of Outsourcing, the In Vitro ADME testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. 490 BioTech
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Dan Close, Chief Scientific Officer
12.3. JRF Global
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

490 BioTech
Aaranya Biosciences
AbbVie
Accelera
Advanced Chemistry Development Labs
Admescope
ADMETRx
Advancell Advanced In Vitro Cell Technologies
Agilux Laboratories
Allesh Biosciences Labs
Altasciences
AMRI
Analiza
Antengene
APEIRON Biologics
APhaD
Apredica
Aptuit
Aragen Bioscience
Aravali Pharma & Lifesciences
Asahi Kasei Pharma
Astellas Analytical Science Laboratories
AstraZeneca
Aurigon
Aurora Fine Chemicals
Avistron Chemistry Services
Baxter
Biaffin
Bienta
BioAscent
Biocon
BioDuro
BioIVT
Bionomics
Biotech Investment Group
Biotranex
BLIRT
BloodCenter of Wisconsin
Blue Stream Laboratories
BOC Sciences
Brains On-Line
BRI Biopharmaceutical Research
Brunswick Labs
Caliper Life Sciences
Calvert Laboratories
CanAm Bioresearch
Cangenix
CapEval Pharma
Carna Biosciences
Carrick Therapeutics
CeeTox
Celgene
Cellumen
Celsis In Vitro Technologies
Celsis International
CEMSA - Center for Applied Mass Spectrometry
Charles River Laboratories
ChemBio Discovery Solutions
ChemDiv
ChemModeling
ChemoGenics BioPharma
Chemotargets
ChemPartner
Citoxlab Group
Clinical Research Laboratories
Cloud Pharmaceuticals
Colorado Computational
Comparative Biosciences
CompChem Solutions
Concept Life Sciences
Concord Biosciences
Corning Life Sciences
Covance
CR Medicon
Creative Animodel
Creative Biolabs
Creative Biostructure
Crelux
Crucell
Cyclica
Cyprotex
Dermscan
DiaSorin
Discover Drugs
Distributed Bio
Domainex
Drik
eADMET
Eagle Pharmaceuticals
ECOSUR
EMD Millipore
Enamine
Entelos
Envigo
EnvironeX Group
Eurofins Scientific
Eurofins Cerep
European Federation of Pharmaceutical Industries and Associations
Eurosafe
Evolvus
Evotec
Excelra Knowledge Solutions
Exscientia
Fidelta
Formex
Frontage Laboratories
Gadea Pharmaceutical Group
Galapagos
Genentech
GenPharm Tox Biotech
Gfree Bio
Gilead Sciences
Greenpharma
GSK
GTCR
GVK Biosciences
HarkerBIO
HD Biosciences
Health Economics Research Centre
Icagen
IDSC
ImaBiotech
In Vitro ADMET Laboratories
Innovative Informatica Technologies
Inpharmatica
InrexTest
INSERM
International Resources Group
INVITEK
IONTOX
IOTA Pharmaceuticals
Japan Pharmaceutical Manufacturers Association
Janssen Therapeutics
JOINN Laboratories
JPT Peptide Technologies
JRF GLOBAL
Jubilant Biosys
Kirklees Biosciences
KWS BioTest
LabCorp
Labo Van Poucke
Laxai Avanti Life Sciences
LegoChem Biosciences
Longthera Pharmaceuticals
Mascot Industries
MasiMax Resources
Mayo Clinic
Medisyn Technologies
Merck
MetaSafe
Metrion Biosciences
MicroConstants
Mind the Byte
Molcode
Molsoft
MorphoSys
MPI Research
MTTlab
Nanolab Technologies
National Institute of Allergy and Infectious Disease
National Institutes of Health
Neuro-Sys
NMDL-LCPL
Notox
NovaData Solutions
Novamass
NovaMechanics
Novartis
Novo Informatics
NuChem Therapeutics
Nuevolution
NuGEN Technologies
Numerate
Oncodesign
Optivia Biotechnology
Oroxcell
Oxford Bioscience Partners
Panlabs Biologics
PathoQuest
PerkinElmer
Petra Pharma
Pfizer
PharmaCadence
Pharmacelsus
Pharmaceuticals and Medical Devices Agency
Pharmaceutical Product Development
Pharmaron
Pharmidex Pharmaceutical Services
PharmOptima
PHAST
Piramal Pharma Solutions
Porton Pharma Solutions
Preclinical GPS
Prestwick Chemical
Prime European Therapeuticals
Princeton BioMolecular Research
Profacgen
ProSciens
Prosilico
ProtoQSAR
ProXyChem
Q2 Solutions
Q3 Analytical
Qualyst Transporter Solutions
Quantum Hi-Tech
Quintara Discovery
Quotient Bioresearch
ReadyCell
Rebexsess Discovery Chemistry
Red Glead Discovery
Regulus Therapeutics
ResearchPoint Global
Rosa
RTI International
Sai Life Sciences
Sandexis
Sanofi
Schrdinger
Sekisui Medical
Sekisui XenoTech
Selcia
Selvita
Shanghai ChemPartner
Shanghai Medicilon
Shechter Computational Solutions
Shire
Sigma-Aldrich
SilcsBio
Simulations Plus
SNBL USA
SOLVO Biotechnology
Spectris
SPEware
SRI International
Strand Life Sciences
Suven Life Sciences
Sygnature Discovery
Syngene
Synovo
Syntegrity Group
TCG Lifesciences
Tecan
TestAmerica
TetraQ
The Carlyle Group
The Institute for Transfusion Medicine
The Michael J Fox Foundation
Touchstone Biosciences
TPG Capital
Triskelion
Unilabs
University of California
University of Pittsburgh
Vanta Bioscience
Villapharma Research
Vipragen Biosciences
Vitalant Research Institute
Viva Biotech
Vivo Bio Tech
Vivotecnia
WIL Research Laboratories
Wildcard Pharmaceutical Consulting
WuXi AppTec
Xceleron
XenoBiotic Laboratories
Xenometrics
XenoTech
XtalPi
Zumutor Biologics

For more information about this report visit https://www.researchandmarkets.com/research/nvq5sb/global_invitro?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets